Short Interest in Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) Decreases By 9.6%

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) saw a large decline in short interest in the month of April. As of April 15th, there was short interest totalling 1,980,000 shares, a decline of 9.6% from the March 31st total of 2,190,000 shares. Based on an average daily trading volume, of 354,100 shares, the short-interest ratio is currently 5.6 days.

Actinium Pharmaceuticals Stock Up 7.4 %

NYSEAMERICAN:ATNM traded up $0.51 on Monday, hitting $7.38. The company’s stock had a trading volume of 244,842 shares, compared to its average volume of 322,240. Actinium Pharmaceuticals has a one year low of $4.00 and a one year high of $9.86. The firm has a market capitalization of $216.97 million, a price-to-earnings ratio of -4.06 and a beta of 0.01.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last issued its quarterly earnings data on Friday, March 29th. The biotechnology company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.21. The business had revenue of $0.08 million during the quarter. Equities research analysts expect that Actinium Pharmaceuticals will post -1.87 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ATNM. StockNews.com lowered Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, March 19th. Cantor Fitzgerald reiterated an “overweight” rating and set a $21.00 price target on shares of Actinium Pharmaceuticals in a research note on Monday, April 1st. HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Actinium Pharmaceuticals in a research note on Monday. Finally, Maxim Group raised their target price on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, March 19th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $25.72.

Hedge Funds Weigh In On Actinium Pharmaceuticals

Several large investors have recently bought and sold shares of ATNM. Sanders Morris Harris LLC bought a new position in shares of Actinium Pharmaceuticals in the 1st quarter worth about $78,000. Creative Financial Designs Inc. ADV increased its position in shares of Actinium Pharmaceuticals by 19.1% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock worth $101,000 after acquiring an additional 3,175 shares in the last quarter. Finally, Brandywine Global Investment Management LLC purchased a new stake in shares of Actinium Pharmaceuticals in the third quarter worth approximately $1,033,000. 27.50% of the stock is currently owned by institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.